Caplin Point Laboratories Ltd (CAPLIPOINT) — shareholding pattern, promoter holding, financials and share price
About Caplin Point Laboratories Ltd (CAPLIPOINT)
Caplin Point Laboratories Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as CAPLIPOINT and on the BSE under scrip code 524742. Its ISIN is INE475E01026.
Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations. [1]
Caplin Point Laboratories is an India‑headquartered pharmaceutical company focused on developing, manufacturing and exporting a broad portfolio of generic formulations and sterile injectables to Latin America, Africa and regulated markets including the US and EU through subsidiaries such as Caplin Steriles and regional distribution units.
Management reports an active and expanding US ANDA pipeline with recent first‑cycle approvals for complex suspension injectables and ophthalmic emulsions, a growing US label business approaching ~$10 million since inception, and an expectation of several more ANDA approvals and launches across FY26–FY28.
Listed peers in Pharmaceuticals: Pfizer Ltd, Astrazeneca Pharma India Ltd, ERIS Lifesciences Ltd, OneSource Specialty Pharma Ltd, Natco Pharma Ltd, Cohance Lifesciences Ltd.
Valuation & Returns
10 Jul 2026At ₹2,603.4 a share on 10 Jul 2026, Caplin Point Laboratories Ltd (CAPLIPOINT) was valued at a price-to-earnings ratio of 30.46x against an industry P/E of 36.41x and a price-to-book of 6.94x on a book value of ₹375.01 per share as of Mar 2025. Solomo computes return on equity of 22.79% and return on capital employed of 28.14% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 30.46x
- Industry P/E
- 36.41x
- P/B
- 6.94x
- EPS (TTM)
- ₹85.48
- Book value / share
- ₹375.01
- ROE
- 22.79%
- ROCE
- 28.14%
- ROA
- 20.25%
- Debt / equity
- 0x
- Dividend yield
- 0.27%
- EBITDA margin
- 40.07%
- 52-week range
- ₹1,502.45 – ₹2,689
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Caplin Point Laboratories Ltd (CAPLIPOINT) reported revenue of ₹2,187 crore, net profit of ₹650 crore and earnings per share of ₹84.36. That compares with revenue of ₹1,937 crore and net profit of ₹541 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹600 crore and net profit ₹173 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 1,269 | 1,467 | 1,694 | 1,937 | 2,187 |
| Net profit (₹ cr) | 308 | 377 | 461 | 541 | 650 |
| EPS (₹) | 39.56 | 49.57 | 60.19 | 70.56 | 84.36 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 14.00% | 7.35% | 12.53% | 14.37% |
| Profit growth | 25.07% | 11.43% | 21.80% | 17.27% |
| Stock price CAGR | 29% | 31% | 45% | 28% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 70.57% of Caplin Point Laboratories Ltd (CAPLIPOINT) (unchanged from the previous quarter), foreign institutional investors (FII) hold 5.75% and domestic institutional investors (DII) hold 2.49%. Market capitalisation was ₹19,789 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: INVESTOR EDUCATION AND PROTECTION FUND AUTHORITY MINISTRY OF CORPORATE AFFAIRS 2.87%, UTI MULTI CAP FUND 1.81%, PINEBRIDGE GLOBAL FUNDS - PINEBRIDGE INDIA EQUITY FUND 1.05%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 70.57% | - | 5.75% | 2.49% | 29.43% |
| Mar 2026 | 70.57% | - | 6.15% | 2.14% | 29.43% |
| Dec 2025 | 70.57% | - | 6.59% | 2.05% | 29.43% |
| Sep 2025 | 70.57% | - | 6.51% | 2.1% | 29.43% |
| Jun 2025 | 70.56% | - | 6.17% | 2.22% | 29.44% |
| Mar 2025 | 70.56% | - | 5.73% | 2.01% | 29.44% |
| Dec 2024 | 70.56% | - | 4.86% | 2.11% | 29.44% |
| Sep 2024 | 70.56% | - | 3.7% | 1.84% | 29.44% |